Stockscreener 앱 받기
14.68
4.78%
0.67
시간 외 거래:
14.50
-0.18
-1.23%
전일 마감가:
$14.01
열려 있는:
$14.06
하루 거래량:
11.77M
Relative Volume:
1.17
시가총액:
$17.09B
수익:
$14.29B
순이익/손실:
$-3.51B
주가수익비율:
-4.959
EPS:
-2.9603
순현금흐름:
$1.85B
1주 성능:
+8.98%
1개월 성능:
+6.38%
6개월 성능:
+44.35%
1년 성능:
+94.18%
1일 변동 폭
$14.06
$14.74
1주일 범위
$13.37
$14.74
52주 변동 폭
$7.465
$16.47
비아트리스 Stock (VTRS) Company Profile
명칭
Viatris Inc
전화
(724) 514-1465
주소
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
14.68 | 17.09B | 14.29B | -3.51B | 1.85B | -2.9603 |
TAK
Takeda Pharmaceutical Co Adr
|
17.82 | 56.30B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
122.38 | 51.46B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.75 | 43.42B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.40 | 37.73B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
588.38 | 25.79B | 3.18B | 1.33B | 1.04B | 27.90 |
비아트리스 Stock (VTRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 업그레이드 | UBS | Neutral → Buy |
| 2026-01-16 | 업그레이드 | Argus | Hold → Buy |
| 2025-12-09 | 개시 | Barclays | Overweight |
| 2025-10-15 | 개시 | Truist | Buy |
| 2025-06-06 | 개시 | Goldman | Neutral |
| 2024-07-19 | 재개 | Jefferies | Buy |
| 2023-10-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2023-06-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2023-04-24 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2023-02-17 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-11-10 | 업그레이드 | UBS | Sell → Neutral |
| 2022-11-08 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | 재개 | Jefferies | Hold |
| 2022-06-14 | 개시 | UBS | Sell |
| 2022-05-10 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-01 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | 개시 | Citigroup | Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Outperform |
| 2021-03-08 | 다운그레이드 | Goldman | Buy → Neutral |
| 2021-03-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-02-26 | 다운그레이드 | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | 개시 | Argus | Hold |
| 2020-12-14 | 개시 | Bernstein | Mkt Perform |
모두보기
비아트리스 주식(VTRS)의 최신 뉴스
Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To Know - Yahoo Finance
Is Viatris Inc (VTRS) Overvalued After 4.7% Rally? GF Value Says - GuruFocus
Viatris Inc. stock rises Friday, outperforms market - MSN
Xanax recalled nationwide due to potential issue with quality, efficacy - National News Desk
Popular anxiety medication recalled nationwide after FDA warning - NewsNation
Xanax XR recalled after discovery that tablets may fail to release medication properly - Fox Business
Viatris (VTRS) CCO nets 107,135 shares after RSU and DEU vesting - Stock Titan
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Why the Xanax recall may not impact your prescription - The Hill
Popular Prescription Medication Xanax Is Being Recalled Nationwide - AOL.com
Xanax from West Virginia-based company recalled nationwide. What you need to know - Yahoo
Xanax bottles recalled nationwide over dissolution issues - WCVB
Anxiety drug Xanax recalled nationwide: How to check if your prescription is included - New York Post
Xanax, popular anxiety medication, recalled: What to know - FOX 13 Tampa Bay
Popular anxiety drug Xanax recalled nationwide: What to know - NBC 5 Chicago
Bottles of Xanax, a popular anxiety drug, recalled nationwide. Here’s why - KFOR.com
Popular anxiety prescription recalled nationwide - WJHL
Bottles of Xanax recalled nationwide. Here’s why - CBS 42
Viatris Ophthalmology Data At ASCRS Puts Valuation And Dividend In Focus - Sahm
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris to Report First Quarter 2026 Financial Results on May 7, 2026 - Lelezard
FDA Recalls and Warnings: Potentially Contaminated Cough Drops and Eye Drops, Subpotent Thyroid Medications & More - MedShadow Foundation
Behavioral Patterns of VTRS and Institutional Flows - Stock Traders Daily
Barclays Maintains Viatris(VTRS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Announces Multiple Data Presentations at ASCRS Annual Meeting - National Today
Night Vision Disturbances Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Opus Genetics, Viatris, Nevakar, Vyluma, Pfizer, Allergan, AbbVie - Barchart.com
Xanax Has Been Recalled Nationwide, According to a New FDA Report - The Healthy @Reader's Digest
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting - ChartMill
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Momentum Shift: Is Viatris Inc impacted by rising ratesWeekly Loss Report & Weekly High Momentum Picks - baoquankhu1.vn
Truist Financial Maintains Viatris(VTRS.US) With Buy Rating - Moomoo
VTRS INVESTOR NOTICE: Viatris, Inc. Investors with Substantial L - GuruFocus
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Viagra Maker Blocks Rival's 'Kamagra' TM - Law360
Viatris sets long-term targets ahead of investor event - MSN
Layoff Tracker: BioNTech will close Singapore plant, affecting 85 employees - BioSpace
How Effexor’s New GAD Approval And MR-139 Setback At Viatris (VTRS) Has Changed Its Investment Story - simplywall.st
Viatris (VTRS) Q4 2025 Earnings Call Transcript - Fortune
Viatris Inc (VIA.HM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Viatris (VTRS) price target increased by 10.80% to 15.70 - MSN
Viatris (VTRS) Valuation In Focus After MR-139 Phase III Failure And Pipeline Setback - simplywall.st
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris (VTRS) 2026 proxy details $14.3B revenue, board refresh and key votes - Stock Titan
Viatris Inc (VIA.HM) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Viatris Inc. (VTRS) Stock forecasts - Yahoo Finance UK
(VTRS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight - Investing.com
Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Named a Great Place To Work in India for the Fifth Consecutive Year - businesswireindia.com
비아트리스 (VTRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
6.22%
3.77%
자본화:
|
볼륨(24시간):